IL272575B2 - Indazole compounds as allosteric enhancers of mglur4, compositions and methods for treating neurological dysfunction - Google Patents
Indazole compounds as allosteric enhancers of mglur4, compositions and methods for treating neurological dysfunctionInfo
- Publication number
- IL272575B2 IL272575B2 IL272575A IL27257520A IL272575B2 IL 272575 B2 IL272575 B2 IL 272575B2 IL 272575 A IL272575 A IL 272575A IL 27257520 A IL27257520 A IL 27257520A IL 272575 B2 IL272575 B2 IL 272575B2
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- chosen
- alkoxy
- compound
- methoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762546290P | 2017-08-16 | 2017-08-16 | |
| PCT/US2018/046801 WO2019036534A1 (en) | 2017-08-16 | 2018-08-16 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIALIZERS, COMPOSITIONS, AND METHODS FOR TREATING NEUROLOGICAL DYSFUNCTIONS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL272575A IL272575A (en) | 2020-03-31 |
| IL272575B1 IL272575B1 (en) | 2023-05-01 |
| IL272575B2 true IL272575B2 (en) | 2023-09-01 |
Family
ID=63579734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL272575A IL272575B2 (en) | 2017-08-16 | 2018-08-16 | Indazole compounds as allosteric enhancers of mglur4, compositions and methods for treating neurological dysfunction |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10508105B2 (enExample) |
| EP (1) | EP3668865A1 (enExample) |
| JP (1) | JP7253832B2 (enExample) |
| KR (1) | KR102687118B1 (enExample) |
| CN (1) | CN111225913B (enExample) |
| AU (1) | AU2018317403B2 (enExample) |
| BR (1) | BR112020003292A2 (enExample) |
| CA (1) | CA3072493A1 (enExample) |
| CL (1) | CL2020000360A1 (enExample) |
| CO (1) | CO2020002576A2 (enExample) |
| EA (1) | EA202090467A1 (enExample) |
| IL (1) | IL272575B2 (enExample) |
| PE (1) | PE20200756A1 (enExample) |
| SG (1) | SG11202001264UA (enExample) |
| UA (1) | UA128084C2 (enExample) |
| WO (1) | WO2019036534A1 (enExample) |
| ZA (1) | ZA202001321B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11319304B2 (en) | 2017-06-28 | 2022-05-03 | Vanderbilt University | Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EA202090467A1 (ru) | 2017-08-16 | 2020-06-18 | Вандербилт Юниверсити | ИНДАЗОЛОВЫЕ СОЕДИНЕНИЯ КАК АЛЛОСТЕРИЧЕСКИЕ ПОТЕНЦИАТОРЫ mGLuR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
| CA3145305A1 (en) | 2019-07-11 | 2021-01-14 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
| EP4447953A1 (en) | 2021-12-13 | 2024-10-23 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| AU2023389404A1 (en) * | 2022-12-08 | 2025-05-22 | Boehringer Ingelheim International Gmbh | Novel substituted pyrazine-carboxamide-imidazopyridine derivatives |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008061109A2 (en) * | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| WO2008067121A2 (en) * | 2006-11-07 | 2008-06-05 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
| WO2016123629A1 (en) * | 2015-01-30 | 2016-08-04 | Vanderbilt University | Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2120932T3 (da) | 2006-12-20 | 2014-10-13 | Nerviano Medical Sciences Srl | Indazolderivater som kinasehæmmere til behandling af kræft |
| GB0713686D0 (en) * | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| CA2751176A1 (en) | 2009-01-28 | 2010-08-05 | Vanderbilt University | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| BR112012001532A2 (pt) | 2009-07-23 | 2019-09-24 | Univ Vanderbilt | "substituída azolesulfonamides benzoimid e indolesulfonamides substituído como potenciadores mglur4" |
| WO2011029104A1 (en) | 2009-09-04 | 2011-03-10 | Vanderbilt University | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| RU2012121633A (ru) | 2009-10-22 | 2013-11-27 | Вандербилт Юниверсити | АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
| AU2010314891A1 (en) | 2009-11-06 | 2012-06-07 | Vanderbilt University | Aryl and heteroaryl sulfones as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| BR112012020273A8 (pt) | 2010-02-11 | 2017-12-26 | Univ Vanderbilt | compostos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno e pirazolotiazol como pontencializadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica |
| JP2013519685A (ja) | 2010-02-11 | 2013-05-30 | ヴァンダービルト ユニバーシティー | ｍＧｌｕＲ４アロステリック増強剤としてのベンズイソオキサゾール類およびアザベンズイソオキサゾール類、組成物、および神経機能不全を治療する方法 |
| EP2568809A4 (en) | 2010-05-12 | 2013-11-06 | Univ Vanderbilt | HETEROCYCLIC ALLOSTERE SULFON MGLUR4 POTENTIATORS, COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| MA39763A (fr) | 2014-03-20 | 2017-01-25 | Samumed Llc | Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| US10221172B2 (en) | 2015-01-13 | 2019-03-05 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US9980945B2 (en) | 2015-01-13 | 2018-05-29 | Vanderbilt University | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10227343B2 (en) | 2015-01-30 | 2019-03-12 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EA202090467A1 (ru) | 2017-08-16 | 2020-06-18 | Вандербилт Юниверсити | ИНДАЗОЛОВЫЕ СОЕДИНЕНИЯ КАК АЛЛОСТЕРИЧЕСКИЕ ПОТЕНЦИАТОРЫ mGLuR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
-
2018
- 2018-08-16 EA EA202090467A patent/EA202090467A1/ru unknown
- 2018-08-16 UA UAA202001405A patent/UA128084C2/uk unknown
- 2018-08-16 SG SG11202001264UA patent/SG11202001264UA/en unknown
- 2018-08-16 JP JP2020508581A patent/JP7253832B2/ja active Active
- 2018-08-16 KR KR1020207007596A patent/KR102687118B1/ko active Active
- 2018-08-16 IL IL272575A patent/IL272575B2/en unknown
- 2018-08-16 BR BR112020003292-1A patent/BR112020003292A2/pt unknown
- 2018-08-16 US US16/104,011 patent/US10508105B2/en active Active
- 2018-08-16 AU AU2018317403A patent/AU2018317403B2/en active Active
- 2018-08-16 CA CA3072493A patent/CA3072493A1/en active Pending
- 2018-08-16 EP EP18769523.4A patent/EP3668865A1/en active Pending
- 2018-08-16 WO PCT/US2018/046801 patent/WO2019036534A1/en not_active Ceased
- 2018-08-16 PE PE2020000257A patent/PE20200756A1/es unknown
- 2018-08-16 US US16/639,539 patent/US11427573B2/en active Active
- 2018-08-16 CN CN201880067616.7A patent/CN111225913B/zh active Active
-
2020
- 2020-02-12 CL CL2020000360A patent/CL2020000360A1/es unknown
- 2020-02-28 ZA ZA2020/01321A patent/ZA202001321B/en unknown
- 2020-03-04 CO CONC2020/0002576A patent/CO2020002576A2/es unknown
-
2022
- 2022-04-26 US US17/730,112 patent/US12291521B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008067121A2 (en) * | 2006-11-07 | 2008-06-05 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
| WO2008061109A2 (en) * | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| WO2016123629A1 (en) * | 2015-01-30 | 2016-08-04 | Vanderbilt University | Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200054204A (ko) | 2020-05-19 |
| UA128084C2 (uk) | 2024-04-03 |
| IL272575A (en) | 2020-03-31 |
| JP2020531454A (ja) | 2020-11-05 |
| KR102687118B1 (ko) | 2024-07-19 |
| AU2018317403A1 (en) | 2020-03-12 |
| EA202090467A1 (ru) | 2020-06-18 |
| US10508105B2 (en) | 2019-12-17 |
| US12291521B2 (en) | 2025-05-06 |
| PE20200756A1 (es) | 2020-07-27 |
| WO2019036534A1 (en) | 2019-02-21 |
| IL272575B1 (en) | 2023-05-01 |
| US11427573B2 (en) | 2022-08-30 |
| EP3668865A1 (en) | 2020-06-24 |
| CA3072493A1 (en) | 2019-02-21 |
| CN111225913B (zh) | 2024-05-31 |
| BR112020003292A2 (pt) | 2020-08-18 |
| JP7253832B2 (ja) | 2023-04-07 |
| CL2020000360A1 (es) | 2020-07-31 |
| CO2020002576A2 (es) | 2020-04-01 |
| AU2018317403B2 (en) | 2023-09-21 |
| US20200291019A1 (en) | 2020-09-17 |
| US20190055225A1 (en) | 2019-02-21 |
| SG11202001264UA (en) | 2020-03-30 |
| US20220259190A1 (en) | 2022-08-18 |
| ZA202001321B (en) | 2023-10-25 |
| CN111225913A (zh) | 2020-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10227343B2 (en) | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| IL272575B2 (en) | Indazole compounds as allosteric enhancers of mglur4, compositions and methods for treating neurological dysfunction | |
| US9180192B2 (en) | mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| US8916584B2 (en) | Benzisoxazoles and azabenzisoxazoles as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| US8759377B2 (en) | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| US10710997B2 (en) | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| US10294222B2 (en) | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| US10526323B2 (en) | Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| MX2012009378A (es) | Compuestos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno y pirazolotiazol como potenciadores alostericos mglur4, composiciones y metodos para tratar disfunciones neurologicas. | |
| WO2011057208A2 (en) | Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| US20180021312A1 (en) | Benzoisoxazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| US20180022744A1 (en) | Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| US11242342B2 (en) | Isoquinoline amine compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| US10968227B2 (en) | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| US11319304B2 (en) | Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| EA043291B1 (ru) | ИНДАЗОЛОВЫЕ СОЕДИНЕНИЯ КАК АЛЛОСТЕРИЧЕСКИЕ ПОТЕНЦИАТОРЫ mGLuR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |